Silipide(Silipide) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

肿瘤感染消化系统疾病+ [2]

在研适应症-

非在研适应症

丙型肝炎慢性丙型肝炎非酒精性脂肪性肝炎+ [1]

原研机构

Sanofi

在研机构-

非在研机构

Sanofi

University of California San Diego

National Center for Complementary and Integrative Health

+ [2]

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Silipide 相关的临床试验

NCT00443079 / Completed临床2期IIT

A Single-center, Single-blinded, Placebo-controlled Pilot Study of IdB 1016 (Siliphos) in Adult Patients With Non-alcoholic Steatohepatitis (NASH)

The purpose of this study is to evaluate the dietary supplement Siliphos, which comes from milk thistle, to determine whether it is safe and well-tolerated in adults who have non-alcoholic steatohepatitis (NASH). An additional aim of this study is to determine whether Siliphos may be beneficial in treatment of NASH as indicated by improvement in liver enzymes (ALT and AST). The study hypothesis is that Siliphos will be safe and well-tolerated in people with NASH and will result in a decrease in the liver enzymes ALT and AST.

开始日期2007-03-01

申办/合作机构

University of California San Diego

[+1]

NCT00055445 / Completed临床1/2期IIT

IdB 1016 in Hepatitis C

This study will measure the safety and tolerability of three different doses of IdB 1016 in patients with hepatitis C disease who have not responded to or are poor candidates for interferon-based therapies.
NOTE: THE STUDY WILL ONLY RECRUIT STUDY PARTICIPANTS AT UNIVERSITY OF WASHINGTON MEDICAL CENTER IN SEATTLE

开始日期2003-11-01

申办/合作机构

National Center for Complementary and Integrative Health

100 项与 Silipide 相关的临床结果

登录后查看更多信息

100 项与 Silipide 相关的转化医学

登录后查看更多信息

100 项与 Silipide 相关的专利（医药）

登录后查看更多信息

20

项与 Silipide 相关的文献（医药）

2008-09-01·Journal of Clinical Gastroenterology3区 · 医学

Silybin Treatment is Associated With Reduction in Serum Ferritin in Patients With Chronic Hepatitis C

3区 · 医学

Article

作者: Kris V. Kowdley ; Sandra Schildt ; Jose Berger ; James E. Nelson ; Donald J. Messner ; Julie M. Bares ; Leanna J. Standish

GOALSThe goal of this study was to examine the effect of a standardized silybin and soy phosphatidylcholine complex (IdB 1016) on serum markers of iron status.BACKGROUNDMilk thistle and its components are widely used as an alternative therapy for liver disease because of purported antioxidant, anti-inflammatory, and iron chelating properties.STUDYThirty-seven patients with chronic hepatitis C and Batts-Ludwig fibrosis stage II, III, or IV were randomized to 1 of 3 doses of IdB 1016 for 12 weeks. Serum ferritin, serum iron, total iron binding capacity, and transferrin-iron saturation were measured at baseline, during treatment, and 4 weeks thereafter. Wilcoxon signed rank tests were used to compare baseline and posttreatment values.RESULTSThere was a significant decrease in serum ferritin from baseline to end of treatment (mean, 244 vs. 215 mug/L; median, 178 vs. 148 mug/L; P=0.0005); 78% of subjects had a decrease in serum ferritin level. There was no significant change in serum iron or transferrin-iron saturation. Multivariate logistic regression analysis in a model that included dose, age, sex, HFE genotype, history of alcohol use, and elevated baseline ferritin levels demonstrated that stage III or IV fibrosis was independently associated with decreased posttreatment serum ferritin level.CONCLUSIONSTreatment with IdB 1016 is associated with reduced body iron stores, especially among patients with advanced fibrosis stage.

2008-07-01·Cancer Chemotherapy and Pharmacology4区 · 医学

Consumption of silibinin, a flavonolignan from milk thistle, and mammary cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma (TAg) mouse

4区 · 医学

Article

作者: William P. Steward ; Richard D. Verschoyle ; Andreas J. Gescher ; Karen Brown

Silibinin is a flavonolignan extracted from milk thistle with cancer chemopreventive activity in preclinical models of prostate and colorectal cancer. A milk thistle extract, of which silibin is a major component, has recently been shown to exacerbate mammary carcinogenesis in two rodent models. We tested the hypothesis that consumption of silibinin or silipide, a silibinin formulation with pharmaceutical properties superior to the unformulated agent, affect breast cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma mouse model. Mice received silibinin or silipide (0.2% silibinin equivalents) with their diet from weaning, and tumour development was monitored by weekly palpation and the number and weight of neoplasms at the end of the experiment. Intervention neither promoted, nor interfered with, tumour development. The result suggests that promotion of carcinogenesis is not a feature of silibinin consistent across rodent models of mammary carcinogenesis.

2008-04-01·European Journal of Cancer1区 · 医学

Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: Relationship with silibinin levels

1区 · 医学

Article

作者: Debbie A. Marsden ; William P. Steward ; Andreas J. Gescher ; Karen Brown ; Richard D. Verschoyle ; Ketan Patel ; Peter Greaves

Silibinin, a flavonolignan from milk thistle seeds, possesses cancer chemopreventive properties in rodent models of carcinogenesis. We tested the hypotheses that silibinin or silipide, silibinin formulated with phospholipids, delays tumour development in TRAMP or Apc(Min) mice, genetic models of prostate or intestinal malignancies, respectively. Mice received silibinin or silipide with their diet (0.2% silibinin equivalents) from weaning. Intervention with silipide reduced the size of well differentiated TRAMP adenocarcinomas by 31%. Silipide and silibinin decreased the incidence of poorly differentiated carcinomas by 61% compared to mice on control diet. Silipide decreased plasma levels of insulin-like growth factor (IGF)-1 by 36%. Levels of circulating IGF binding protein (IGFBP)-3 in mice on silipide or silibinin were 3.9- or 5.9-fold, respectively, elevated over those in control TRAMP mice. In Apc(Min) mice silibinin, but not silipide, had only a marginal adenoma number-reducing effect. The results cautiously support the advancement of silipide to the stage of clinical investigation in prostate cancer.

100 项与 Silipide 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非酒精性脂肪性肝炎	临床2期	美国	University of California San Diego	2007-03-01
慢性丙型肝炎	临床2期	美国	National Center for Complementary and Integrative Health	2003-11-01
丙型肝炎	临床2期	-	Sanofi	-
丙型肝炎	临床2期	-	Indena SpA	-
卵巢癌	临床2期	-	Sanofi	-
卵巢癌	临床2期	意大利	Indena SpA	-